vidarabine has been researched along with pf 3084014 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Aymerich, M; Campo, E; Colomer, D; López-Guerra, M; López-Otín, C; Matas-Céspedes, A; Montraveta, A; Pérez-Galán, P; Roldán, J; Rosich, L; Roué, G; Villamor, N; Xargay-Torrent, S | 1 |
2 other study(ies) available for vidarabine and pf 3084014
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.
Topics: Aged; Amyloid Precursor Protein Secretases; Enzyme Inhibitors; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Receptor, Notch1; Tetrahydronaphthalenes; Tumor Cells, Cultured; Valine; Vidarabine | 2015 |